KRSA
Korsana Biosciences, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- E Sep 9 Trading halt: Halt Resumed: KRSA — trading resumed after LUDP (Volatilit…
- A Sep 11 UBS initiates
- A Sep 14 2 analysts initiate
- X Sep 15 Short interest falls 75.4% to 4.4K
- A Sep 28 Guggenheim initiates
- X Sep 30 Short interest jumps 160.1% to 11.6K
- A Oct 5 Wedbush initiates
- X Oct 15 Short interest jumps 106.1% to 23.8K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- AnalystsBULLISH
9 of 10 rate it Buy or better. Median target $44.00 (+46%).
- Short sellersBUILDING
Short interest +106.1% to 23.8K shares. 1.0 days to cover, ≈0.1% of shares.
- TrendDOWNTREND
3% below its 50-day average.
The Street
10 analystsPrice is inside the target range. Median implies +46%.Targets as of Oct 28, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 5, 2026 | Wedbush INITIATE | Outperform |
| Sep 28, 2026 | Guggenheim INITIATE | Buy |
| Sep 14, 2026 | Stifel INITIATE | Buy |
| Sep 14, 2026 | TD Cowen INITIATE | Buy |
| Sep 11, 2026 | UBS INITIATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 9, 2026 | Shah Nimish P Director | AWARD | 48,445 sh |
| Sep 9, 2026 | Pernice Michelle Patricia Director | AWARD | 48,445 sh |
| Sep 9, 2026 | Fairmount Funds Management LLC Director | AWARD | 48,445 sh |
| Sep 9, 2026 | Gottesdiener Andrew Director | AWARD | 48,445 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | -$0.67 | -$0.67–-$0.67 | — | $0.00 |
| Current FY | -$1.70 | -$1.70–-$1.70 | — | $0.00 |
| Next FY | -$3.56 | -$3.56–-$3.56 | — | $0.00 |
Short side
FINRA· Oct 15, 2026| Sep 9, 2026 | Volatility Pause | Resumed |
| Sep 8, 2026 | Resumption Scheduled | Resumed |
SecBot reports
8 filings · 0 bullish · 0 bearish · 8 neutral- NEUTRAL 144Oct 22, 2026
Director Michael J. Higgins filed a Form 144 notice of intent to sell 1,107 shares of Korsana…
The proposed sale is de minimis and routine for a director. No material read-through — monitor for any larger insider sales or changes in beneficial ownership filings.
- NEUTRAL SC 13G/AOct 15, 2026
J. Wood Capital Advisors LLC filed an amended Schedule 13G disclosing a passive stake of 25,974…
J. Wood Capital's 0.1% stake is trivial and does not signal conviction or intent. Monitor for larger institutional filings post-merger to gauge real ownership shifts.
- NEUTRAL DEF 14AOct 15, 2026
Korsana Biosciences is resubmitting a proposal to redomesticate from Massachusetts to the Cayman…
Monitor the vote on Proposal No. 1 requires two-thirds of all outstanding shares — any non-vote counts as a vote AGAINST — making turnout the key variable. If the activist Venrock (9.99% stake) may…
- NEUTRAL 144Sep 23, 2026
Director Errol B. De Souza filed a Form 144 to sell 4,903 shares of Korsana Biosciences common…
Monitor whether the sale is actually executed on Form 4; a director selling a modest number of vested RSU shares is routine and not indicative of negative outlook. No immediate catalyst.
All KRSA filing & press-release reports (8)
- 144 reportOct 22, 2026
- SC 13G/A reportOct 15, 2026
- DEF 14A reportOct 15, 2026
- 144 reportSep 23, 2026
- 144 reportSep 22, 2026
- SC 13G reportSep 18, 2026
- 144 reportSep 18, 2026
- SC 13G reportSep 16, 2026